A pharmaceutical jack of all trades? Novo CEO touts
semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Novo Nordisk’s
recent growth renaissance has flourished thanks in no small part to
semaglutide—the GLP-1 molecule behind the company’s leading trio of Ozempic,
Rybelsus and Wegovy. But even as the drug's metabolic empire prospers, Novo
Nordisk isn’t letting its GLP-1 rest on its laurels.
No comments:
Post a Comment